Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Marin

Showing results (41-50 of 179) with videos related to

Pageof 18
Sort By:
Uchu Seibutsu Kagaku|August 5, 2003
Allelopathy as a new strategy for sustainable ecosystems developmentFrancisco A Macias, David Marin, Alberto Oliveros-Bastidas, et al.
British Journal of Haematology|November 14, 2013
Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effectsPratap Neelakantan, Katayoun Rezvani, Philippa May, et al.
Cancer|March 24, 2005
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinibDavid Marin, Jaspal S Kaeda, Catharina Andreasson, et al.
Blood|May 31, 2012
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinibDavid Marin, Corinne Hedgley, Richard E Clark, et al.
Blood|October 6, 2007
Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemiaValeria A S De Melo, Dragana Milojkovic, Jamshid S Khorashad, et al.
American Journal of Hematology|June 23, 2009
Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemiaLetizia Foroni, Gareth Gerrard, Emmanuel Nna, et al.
Blood|March 16, 2002
Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemiaJyoti Wadhwa, Richard M Szydlo, Jane F Apperley, et al.
Blood|September 21, 2007
Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutationHugues de Lavallade, Jamshid S Khorashad, Howard P Davis, et al.
Blood|August 14, 2010
Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal responseAya Kuwabara, Anna Babb, Amr Ibrahim, et al.
Leukemia & Lymphoma|June 28, 2016
Stem cell transplantation outcomes in lymphoblastic lymphomaJonathan E Brammer, Issa Khouri, David Marin, et al.
Pageof 18

Showing results (41-50 of 179) with videos related to

Sort By:
Pageof 18
Uchu Seibutsu Kagaku|August 5, 2003
Allelopathy as a new strategy for sustainable ecosystems developmentFrancisco A Macias, David Marin, Alberto Oliveros-Bastidas, et al.
British Journal of Haematology|November 14, 2013
Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effectsPratap Neelakantan, Katayoun Rezvani, Philippa May, et al.
Cancer|March 24, 2005
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinibDavid Marin, Jaspal S Kaeda, Catharina Andreasson, et al.
Blood|May 31, 2012
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinibDavid Marin, Corinne Hedgley, Richard E Clark, et al.
Blood|October 6, 2007
Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemiaValeria A S De Melo, Dragana Milojkovic, Jamshid S Khorashad, et al.
American Journal of Hematology|June 23, 2009
Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemiaLetizia Foroni, Gareth Gerrard, Emmanuel Nna, et al.
Blood|March 16, 2002
Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemiaJyoti Wadhwa, Richard M Szydlo, Jane F Apperley, et al.
Blood|September 21, 2007
Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutationHugues de Lavallade, Jamshid S Khorashad, Howard P Davis, et al.
Blood|August 14, 2010
Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal responseAya Kuwabara, Anna Babb, Amr Ibrahim, et al.
Leukemia & Lymphoma|June 28, 2016
Stem cell transplantation outcomes in lymphoblastic lymphomaJonathan E Brammer, Issa Khouri, David Marin, et al.
Pageof 18